Adaptive Biotechnologies (ADPT) Expected to Announce Quarterly Earnings on Thursday

Adaptive Biotechnologies (NASDAQ:ADPT) is projected to post its Q4 2025 results after the market closes on Thursday, February 5th. Analysts expect the company to announce earnings of ($0.19) per share and revenue of $59.3830 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 5, 2026 at 4:30 PM ET.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its earnings results on Wednesday, November 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. The company had revenue of $93.97 million for the quarter, compared to analyst estimates of $58.76 million. Adaptive Biotechnologies had a negative return on equity of 58.40% and a negative net margin of 31.50%.Adaptive Biotechnologies’s quarterly revenue was up 102.4% on a year-over-year basis. During the same period in the prior year, the company posted ($0.22) EPS. On average, analysts expect Adaptive Biotechnologies to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Adaptive Biotechnologies Stock Performance

ADPT opened at $18.50 on Thursday. The company has a market capitalization of $2.82 billion, a P/E ratio of -34.26 and a beta of 2.18. The company has a 50-day moving average of $17.26 and a 200-day moving average of $14.90. Adaptive Biotechnologies has a 1-year low of $6.26 and a 1-year high of $20.76.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ADPT. BTIG Research increased their price target on Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, January 21st. Wall Street Zen raised Adaptive Biotechnologies from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Guggenheim boosted their price target on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a “buy” rating in a report on Monday. Finally, JPMorgan Chase & Co. upped their price target on shares of Adaptive Biotechnologies from $17.00 to $20.00 and gave the stock an “overweight” rating in a research report on Thursday, November 6th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Adaptive Biotechnologies has a consensus rating of “Moderate Buy” and an average price target of $17.22.

Insider Transactions at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, insider Harlan S. Robins sold 27,212 shares of the company’s stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $18.61, for a total value of $506,415.32. Following the transaction, the insider owned 1,242,312 shares of the company’s stock, valued at approximately $23,119,426.32. This represents a 2.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Kyle Piskel sold 162,820 shares of the business’s stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $19.50, for a total transaction of $3,174,990.00. Following the sale, the chief financial officer owned 216,637 shares in the company, valued at $4,224,421.50. This represents a 42.91% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 1,442,530 shares of company stock valued at $24,610,748 in the last 90 days. 6.40% of the stock is owned by corporate insiders.

Institutional Trading of Adaptive Biotechnologies

A number of institutional investors have recently bought and sold shares of the company. Caxton Associates LLP bought a new stake in shares of Adaptive Biotechnologies in the 1st quarter worth about $93,000. Quadrant Capital Group LLC acquired a new position in Adaptive Biotechnologies in the third quarter valued at about $133,000. Captrust Financial Advisors grew its stake in Adaptive Biotechnologies by 7.6% during the second quarter. Captrust Financial Advisors now owns 15,762 shares of the company’s stock worth $184,000 after buying an additional 1,119 shares during the last quarter. Canada Pension Plan Investment Board grew its stake in Adaptive Biotechnologies by 50.8% during the second quarter. Canada Pension Plan Investment Board now owns 19,900 shares of the company’s stock worth $232,000 after buying an additional 6,700 shares during the last quarter. Finally, CIBC Bancorp USA Inc. acquired a new stake in shares of Adaptive Biotechnologies during the third quarter worth approximately $238,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.